Pre-conditioning of Equine Bone Marrow-Derived Mesenchymal Stromal Cells Increases Their Immunomodulatory Capacity.
Authors: Caffi Valeria, Espinosa Gabriel, Gajardo Gonzalo, Morales Natalia, Durán María Carolina, Uberti Benjamín, Morán Gabriel, Plaza Anita, Henríquez Claudio
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Equine bone marrow-derived mesenchymal stromal cells (MSCs) have gained traction as a therapeutic tool for inflammatory and degenerative conditions, yet the precise immunomodulatory mechanisms remain poorly characterised in horses. Caffi and colleagues investigated which molecular pathways enable equine MSCs to suppress lymphocyte proliferation, and whether pre-treating these cells with pro-inflammatory cytokines (TNF-α and IFN-γ) could enhance their anti-inflammatory potency. The research identified two critical enzymes—prostaglandin-endoperoxide synthase 2 and indoleamine 2,3-dioxygenase—as the primary mediators of lymphocyte suppression, and demonstrated that pre-conditioning MSCs with TNF-α, IFN-γ, or both significantly upregulated these enzymes alongside iNOS and IL-6 expression, resulting in substantially stronger inhibition of lymphocyte proliferation. These findings suggest that therapeutic efficacy of MSC treatments could be substantially improved through strategic pre-conditioning protocols before clinical application, offering practitioners a tangible route to optimise cellular therapeutics for managing inflammatory musculoskeletal and soft tissue injuries where excessive lymphocyte activity perpetuates pathology.
Read the full abstract on PubMed
Practical Takeaways
- •Pre-conditioning protocols may enhance the therapeutic efficacy of MSC treatments for inflammatory and degenerative conditions in horses by boosting their anti-inflammatory capacity
- •Understanding that equine MSC effectiveness depends on specific molecular pathways (COX-2 and IDO) could help optimize cell preparation before clinical application
- •Future clinical applications may benefit from standardized pre-conditioning approaches, though clinical translation still requires further in vivo validation
Key Findings
- •Equine bone marrow-derived MSCs inhibit lymphocyte proliferation through prostaglandin-endoperoxide synthase 2 and indoleamine 2,3-dioxygenase activity
- •Pre-conditioning with TNF-α, IFN-γ, or their combination significantly increased expression of immunomodulatory mediators (PGE2 synthase, IDO, iNOS, IL-6)
- •Pre-conditioned MSCs demonstrated increased inhibitory effects on lymphocyte proliferation compared to untreated MSCs